ASCO 2017.
Oasi ALK
Oasi ALK - ASCO2017
Contributi
Video, Slide, Cartelle Zip
ASCO 2017 – ALK – 06/06/2017
Alectinib versus crizotinib in treatment-naive advanced ALK-positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study
A cura di Cesare Gidelli
Diventa socio AIOT, entra e compila il form di registrazione.
